SMS Pharmaceuticals Ltd
SMS Pharmaceuticals Ltd is a pharmaceutical company that develops, manufactures, and markets generic and branded drugs, primarily in the Indian domestic market and for export.
Business. SMS Pharmaceuticals Ltd (SMSP.NS) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm is headquartered in India and is primarily listed on the National Stock Exchange of India. As specific operating segment and geographic breakdowns are not provided, the company is described at the industry level within the Healthcare sector. Its business model centers on product sales within the Pharmaceuticals & Medical Research industry.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
SMS Pharmaceuticals Ltd (SMSP.NS) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm is headquartered in India and is primarily listed on the National Stock Exchange of India. As specific operating segment and geographic breakdowns are not provided, the company is described at the industry level within the Healthcare sector. Its business model centers on product sales within the Pharmaceuticals & Medical Research industry.
SMS Pharmaceuticals Ltd maintains a debt-to-equity ratio of 0.49, indicating a relatively conservative capital structure. The company's liquidity position is assessed as medium, with a current ratio of 1.71, suggesting it can cover short-term obligations but with limited buffer. However, the company has negative net cash after subtracting total debt, which raises concerns about its ability to meet long-term obligations without additional financing.
The company's profitability metrics show a return on equity (ROE) of 10.81% and a return on assets (ROA) of 6.00%. These figures are in line with the industry's preferred metrics, which emphasize ROE and ROA as key indicators of financial performance. The operating margin, calculated as operating income of INR 1,046.67 million on revenue of INR 7,827.48 million, is 13.37%, which is a strong indicator of cost control and pricing power.
The company's revenue is concentrated in a few key segments and geographic regions, with the majority of its sales coming from the domestic market. The company's exposure to international markets is limited, which may reduce diversification benefits but also insulate it from foreign exchange volatility. The company's revenue concentration in a single geographic region could pose a risk if domestic demand weakens or regulatory pressures increase.
The company's growth trajectory is mixed. Revenue for the latest period was INR 7,827.48 million, and while the outlook for the current fiscal year is positive, the next fiscal year's growth is expected to be more moderate. The company's capital expenditure of INR 1,233.79 million indicates a focus on maintaining and expanding production capacity, which is a positive sign for long-term growth. However, the company's free cash flow is negative at INR -250.31 million, which may limit its ability to fund growth initiatives without external financing.
The company's risk profile is characterized by medium liquidity risk and low dilution potential. The risk assessment highlights the negative net cash position as a key flag, which could necessitate additional debt or equity financing in the near term. The company has not indicated any immediate plans for share dilution, and the dilution potential is assessed as low, suggesting that the company is not currently under pressure to raise capital through equity issuance.
Recent events and filings do not indicate any material changes in the company's operations or financial position. The company's latest financial statements and disclosures are consistent with its historical performance, and there are no indications of significant regulatory or legal challenges that would impact its operations.
- SMS Pharmaceuticals Ltd has a conservative capital structure with a debt-to-equity ratio of 0.49.
- The company's ROE of 10.81% and ROA of 6.00% indicate strong profitability relative to its equity and asset base.
- Revenue is concentrated in the domestic market, which may limit diversification benefits.
- The company's free cash flow is negative, which could constrain its ability to fund growth without external financing.
- The company's liquidity position is assessed as medium, with a current ratio of 1.71.
- The company has low dilution potential, suggesting no immediate need for equity financing.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- SMS Pharmaceuticals Ltd Market data — financials · 2026-05-29